)
)
Vita 34 Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Vita 34 AG
Access all reports
Vita 34 AG engages in the collection, preparation, cryopreservation, and storage of stem cells from umbilical cord blood and tissue in Europe. The company also manufactures and sells reagents for bone marrow diagnostics. Its products include frozen cord blood units, partal bio-banking, culture and expansion f IMR90 K1, hematopoietic stem cells, adult progenitor cells, endothelial progenitor cells Mitomycin C; Vitapur; Vitafrost; Vitastem ampoules; sweet-hand sterilization bags for various applications; freezing bag for ten freezing bags; and pipette with tips. The company was founded in 1997 and is headquartered in Leipzig, Germany.
Latest articles
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
)
Mips: The Gore-Tex of Brain Protection
How Mips turned a critical safety flaw into a global success, redefining helmet protection with its technology and ingredient brand business model.
24 Jan 2025
Ticker symbol
V3V
Country
🇩🇪 Germany